Virtus ETF Advisers LLC grew its position in Xencor Inc (NASDAQ:XNCR) by 18.9% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 8,514 shares of the biopharmaceutical company’s stock after acquiring an additional 1,354 shares during the quarter. Virtus ETF Advisers LLC’s holdings in Xencor were worth $348,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Quantamental Technologies LLC bought a new stake in shares of Xencor in the 2nd quarter valued at approximately $76,000. Aperio Group LLC bought a new position in Xencor during the 2nd quarter worth $152,000. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Xencor by 42.2% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,911 shares of the biopharmaceutical company’s stock worth $160,000 after buying an additional 1,160 shares during the last quarter. Bank of Montreal Can bought a new position in Xencor during the 2nd quarter worth $163,000. Finally, Shell Asset Management Co. bought a new position in Xencor during the 1st quarter worth $145,000. Institutional investors and hedge funds own 84.00% of the company’s stock.

In other news, VP John R. Desjarlais sold 35,000 shares of the stock in a transaction on Monday, August 19th. The stock was sold at an average price of $40.69, for a total value of $1,424,150.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider John J. Kuch sold 40,000 shares of the stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $41.27, for a total value of $1,650,800.00. The disclosure for this sale can be found here. Corporate insiders own 4.33% of the company’s stock.

A number of brokerages recently commented on XNCR. Piper Jaffray Companies upped their price objective on Xencor from $56.00 to $67.00 and gave the stock an “overweight” rating in a research note on Monday, July 8th. Mizuho restated a “buy” rating and set a $52.00 price objective on shares of Xencor in a research note on Monday, July 1st. Raymond James restated a “market perform” rating on shares of Xencor in a research note on Wednesday, August 7th. Leerink Swann set a $52.00 price objective on Xencor and gave the stock a “buy” rating in a research note on Wednesday, August 7th. Finally, Wedbush upped their price objective on Xencor from $43.00 to $54.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 7th. They noted that the move was a valuation call. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $44.62.

XNCR traded down $0.10 during trading on Friday, reaching $35.38. 251,194 shares of the company were exchanged, compared to its average volume of 317,375. Xencor Inc has a 52 week low of $27.75 and a 52 week high of $48.38. The stock has a market cap of $2.06 billion, a P/E ratio of -27.01 and a beta of 1.44. The firm has a 50 day moving average of $39.29 and a 200 day moving average of $35.45. The company has a current ratio of 8.27, a quick ratio of 8.27 and a debt-to-equity ratio of 0.02.

Xencor (NASDAQ:XNCR) last released its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.45) by $0.15. Xencor had a return on equity of 8.40% and a net margin of 28.46%. The company had revenue of $19.49 million during the quarter, compared to analysts’ expectations of $7.58 million. As a group, analysts forecast that Xencor Inc will post 0.05 earnings per share for the current fiscal year.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.

Further Reading: What is an overbought condition?

Want to see what other hedge funds are holding XNCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xencor Inc (NASDAQ:XNCR).

Institutional Ownership by Quarter for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.